- Home
- PNF vs CNTX Comparison
PNF vs CNTX Comparison
Compare PNF & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNF
- CNTX
- Stock Information
- Founded
- PNF 2001
- CNTX 2015
- Country
- PNF United States
- CNTX United States
- Employees
- PNF N/A
- CNTX N/A
- Industry
- PNF Finance Companies
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- PNF Finance
- CNTX Health Care
- Exchange
- PNF Nasdaq
- CNTX Nasdaq
- Market Cap
- PNF 54.1M
- CNTX 60.7M
- IPO Year
- PNF N/A
- CNTX 2021
- Fundamental
- Price
- PNF $7.10
- CNTX $0.77
- Analyst Decision
- PNF
- CNTX Strong Buy
- Analyst Count
- PNF 0
- CNTX 6
- Target Price
- PNF N/A
- CNTX $6.50
- AVG Volume (30 Days)
- PNF 29.1K
- CNTX 96.5K
- Earning Date
- PNF 01-01-0001
- CNTX 05-07-2025
- Dividend Yield
- PNF 5.17%
- CNTX N/A
- EPS Growth
- PNF N/A
- CNTX N/A
- EPS
- PNF N/A
- CNTX N/A
- Revenue
- PNF N/A
- CNTX N/A
- Revenue This Year
- PNF N/A
- CNTX N/A
- Revenue Next Year
- PNF N/A
- CNTX N/A
- P/E Ratio
- PNF N/A
- CNTX N/A
- Revenue Growth
- PNF N/A
- CNTX N/A
- 52 Week Low
- PNF $6.37
- CNTX $0.55
- 52 Week High
- PNF $9.06
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- PNF 49.17
- CNTX 44.11
- Support Level
- PNF $6.95
- CNTX $0.74
- Resistance Level
- PNF $7.21
- CNTX $0.90
- Average True Range (ATR)
- PNF 0.10
- CNTX 0.09
- MACD
- PNF 0.04
- CNTX -0.02
- Stochastic Oscillator
- PNF 73.17
- CNTX 11.07
About PNF PIMCO New York Municipal Income Fund
PIMCO New York Municipal Income Fund is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund's portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.